The Evolving Role of Metastasectomy for Patients with Metastatic Renal Cell Carcinoma

Abstract

Surgical metastasectomy continues to be utilized for patients with solitary or low-volume metastatic renal cell carcinoma (mRCC). Although few high-quality data are available to evaluate outcomes, local treatment is recommended when feasible because it may allow a subset of patients to delay or avoid systemic treatments. With the development of improved mRCC therapies, utilization of metastasectomy has increased because most patients have incomplete responses to systemic treatment of their metastases. This review discusses the rationale and history of metastasectomy, trends in utilization, prognostic factors for patient selection, site-specific considerations, alternatives for nonsurgical local treatment, and risk of morbidity associated with metastasectomy.

Keywords: Immune checkpoint inhibitors; Immunotherapy; Metastasectomy; Metastatic renal cell carcinoma; Prognostic factors; Radiation; Targeted therapy; Thermal ablation.